bluebird bio, Inc.
NASDAQ:BLUE
Overview | Financials
| Company Name | bluebird bio, Inc. |
| Symbol | BLUE |
| Currency | USD |
| Price | 4.97 |
| Market Cap | 48,668,526 |
| Dividend Yield | 0% |
| 52-week-range | 3.2 - 28.6 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Andrew Obenshain |
| Website | https://www.bluebirdbio.com |
An error occurred while fetching data.
About bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD









